Home/Filings/4/0001062993-25-002561
4//SEC Filing

Rottinghaus Scott T. 4

Accession 0001062993-25-002561

CIK 0001177648other

Filed

Feb 13, 7:00 PM ET

Accepted

Feb 14, 4:42 PM ET

Size

6.5 KB

Accession

0001062993-25-002561

Insider Transaction Report

Form 4
Period: 2025-02-12
Rottinghaus Scott T.
Chief Medical Officer
Transactions
  • Award

    Common Stock

    2025-02-12+9,75027,668 total
  • Tax Payment

    Common Stock

    2025-02-12$5.59/sh2,861$15,99324,807 total
Footnotes (2)
  • [F1]Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025.
  • [F2]Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards.

Issuer

ENANTA PHARMACEUTICALS INC

CIK 0001177648

Entity typeother

Related Parties

1
  • filerCIK 0001942407

Filing Metadata

Form type
4
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:42 PM ET
Size
6.5 KB